Last reviewed · How we verify
NB002
At a glance
| Generic name | NB002 |
|---|---|
| Sponsor | Suzhou Neologics Bioscience Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NB002 CI brief — competitive landscape report
- NB002 updates RSS · CI watch RSS
- Suzhou Neologics Bioscience Co., Ltd. portfolio CI